Aripiprazole and Extrapyramidal Symptoms

Risk Profile and Clinical Evidence

Aripiprazole is classified as "less likely to cause EPSEs" according to major clinical practice guidelines, distinguishing it from high-potency typical antipsychotics like haloperidol and even some second-generation agents 1
The 2025 INTEGRATE guidelines specifically note aripiprazole's favorable EPS profile when recommending it for negative symptoms in schizophrenia, as stated by the guideline society 2

When prescribing aripiprazole, start with the lowest effective dose and avoid rapid escalation, as recommended by clinical guidelines 3
Monitor closely for EPS, particularly in adolescents, males, and those with greater symptom severity, and consider dose reduction as first-line management if EPS develops, according to the guideline society 3
Aripiprazole remains a preferred option when EPS risk is a concern compared to typical antipsychotics and higher-risk atypical agents, but clinicians must remain vigilant for these adverse effects, particularly at higher doses and in vulnerable populations, as noted by the American College of Psychiatry 1, 2